Tag: therapy

MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to one new non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.

The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other...

The delta-like ligand 3 targeted therapies market is witnessing significant growth, driven by the rising incidence of small cell lung cancer (SCLC) and neuroendocrine...

As Part of the Brand’s Ongoing Efforts for Remaining a Best Choice Amongst All The Online Casinos Canada, RoboCat Has Renovated Their Online Slots and Instant Games Sections with New Titles and Exclusive Bonuses

As Part of the Brand’s Ongoing Efforts for Remaining a Best Choice Amongst All The Online Casinos Canada, RoboCat Has Renovated Their Online Slots and Instant Games Sections with New Titles and Exclusive Bonuses

PUNE, India, June 19, 2025 /PRNewswire/ -- According to a recent market analysis published by Credence Research Inc., the global Biological Safety Cabinets (BSCs) market...

Inmispace, a global wellness company, will host a corporate workshop in Singapore focused on leadership, burnout prevention, and resilience. Led by founder

LENEXA, Kan., June 19, 2025 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced interim results from an ongoing clinical...

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research 

Research Published in NEJM Evidence and presented at the International Conference on Malignant Lymphoma NEW BRUNSWICK, N.J. and BOSTON, June 19, 2025 /PRNewswire/ -- Researchers from...

Industry vendors team up to support radiation oncology clinics nationwide BOONE, N.C., June 19, 2025 /PRNewswire/ -- Fuse Oncology, an oncology healthcare software solutions provider,...

If approved, Zemcelpro® is expected to:increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromesbe...

Theranica is presenting three real-world evidence studies at the American Headache Society (AHS) 67th Annual Scientific Congress.

LINDON, Utah, June 19, 2025 /PRNewswire/ -- Aspen Laser Systems, LLC and TheraLight, LLC, pioneers in photobiomodulation and integrative wellness technologies, are pleased to...